Safety and Tolerability of Rituximab in Neuromyelitis Optica

NCT00501748 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Neuromyelitis Optica

Interventions

DRUG: Rituximab

Sponsor

University of California, San Francisco

Collaborators

[object Object]